170 related articles for article (PubMed ID: 34253417)
21. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
McLaughlin JM; Jiang Q; Isturiz RE; Sings HL; Swerdlow DL; Gessner BD; Carrico RM; Peyrani P; Wiemken TL; Mattingly WA; Ramirez JA; Jodar L
Clin Infect Dis; 2018 Oct; 67(10):1498-1506. PubMed ID: 29790925
[TBL] [Abstract][Full Text] [Related]
22. Indirect effects of 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in children hospitalised with acute respiratory infection despite heterogeneous vaccine coverage: an observational study in Lao People's Democratic Republic.
Chan J; Lai JYR; Nguyen CD; Vilivong K; Dunne EM; Dubot-Pérès A; Fox K; Hinds J; Moore KA; Nation ML; Pell CL; Xeuatvongsa A; Vongsouvath M; Newton PN; Mulholland K; Satzke C; Dance DAB; Russell FM;
BMJ Glob Health; 2021 Jun; 6(6):. PubMed ID: 34108146
[TBL] [Abstract][Full Text] [Related]
23. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey.
Gönüllü E; Soysal A; Yıldız I; Aydemir G; Tunç T; Karaböcüoğlu M
Hum Vaccin Immunother; 2020 Oct; 16(10):2504-2508. PubMed ID: 32119602
[TBL] [Abstract][Full Text] [Related]
24. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.
Rodrigo C; Bewick T; Sheppard C; Greenwood S; Mckeever TM; Trotter CL; Slack M; George R; Lim WS
Eur Respir J; 2015 Jun; 45(6):1632-41. PubMed ID: 25792633
[TBL] [Abstract][Full Text] [Related]
25. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
[TBL] [Abstract][Full Text] [Related]
26. Pneumococcal conjugate vaccines decrease community-acquired alveolar pneumonia with and without pleural effusion in children <60 months in Southern Israel, 2002-2016.
Triadou D; Givon-Lavi N; Greenberg D; Ben-Shimol S
Infect Dis (Lond); 2020 Mar; 52(3):186-195. PubMed ID: 31774020
[No Abstract] [Full Text] [Related]
27. Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia.
Forstner C; Kolditz M; Kesselmeier M; Ewig S; Rohde G; Barten-Neiner G; Rupp J; Witzenrath M; Welte T; Pletz MW;
Vaccine; 2020 Jan; 38(5):1129-1136. PubMed ID: 31761500
[TBL] [Abstract][Full Text] [Related]
28. The rationale for use of clinically defined outcomes in assessing the impact of pneumococcal conjugate vaccines against pneumonia.
Gessner BD; Isturiz R; Snow V; Grant LR; Theilacker C; Jodar L
Expert Rev Vaccines; 2021 Mar; 20(3):269-280. PubMed ID: 33602035
[No Abstract] [Full Text] [Related]
29. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
Isturiz R; Webber C
Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
[TBL] [Abstract][Full Text] [Related]
30. Incidence, aetiology and serotype coverage for pneumococcal vaccines of community-acquired pneumonia in adults: a population-based prospective active surveillance study in Brazil.
Duarte FG; Barberino MG; da Silva Moreira S; Reis JN; Spinardi JR; de Almeida RS; Allen KE; Alexander-Parrish R; Brim R; de Araújo Neto CA; Moreira ED
BMJ Open; 2022 Apr; 12(4):e059824. PubMed ID: 35428648
[TBL] [Abstract][Full Text] [Related]
31. Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine.
Hsiao A; Hansen J; Timbol J; Lewis N; Isturiz R; Alexander-Parrish R; McLaughlin JM; Gessner BD; Klein NP
JAMA Netw Open; 2022 Mar; 5(3):e221111. PubMed ID: 35302634
[TBL] [Abstract][Full Text] [Related]
32. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
Chalmers JD; Campling J; Dicker A; Woodhead M; Madhava H
BMC Pulm Med; 2016 May; 16(1):77. PubMed ID: 27169895
[TBL] [Abstract][Full Text] [Related]
33. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.
Isturiz RE; Hall-Murray C; McLaughlin JM; Snow V; Schmoele-Thoma B; Webber C; Thompson A; Scott DA
Expert Rev Vaccines; 2018 Jan; 17(1):45-55. PubMed ID: 29183235
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Medically Attended Lower Respiratory Tract Infection and Pneumonia Among Older Adults.
Lewnard JA; Bruxvoort KJ; Fischer H; Hong VX; Grant LR; Jódar L; Cané A; Gessner BD; Tartof SY
Clin Infect Dis; 2022 Sep; 75(5):832-841. PubMed ID: 34967907
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
[TBL] [Abstract][Full Text] [Related]
36. Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults.
Isturiz R; Grant L; Gray S; Alexander-Parrish R; Jiang Q; Jodar L; Peyrani P; Ford KD; Pride MW; Self WH; Counselman F; Volturo G; Ostrosky-Zeichner L; Wunderink RG; Sherwin R; Overcash JS; File T; Ramirez J
Clin Infect Dis; 2021 Oct; 73(7):1216-1222. PubMed ID: 33982098
[TBL] [Abstract][Full Text] [Related]
37. Community-Acquired Pneumococcal Pneumonia in Highly Vaccinated Population: Analysis by Serotypes, Vaccination Status, and Underlying Medical Conditions.
Hyun H; Jang AY; Suh JW; Bae IG; Choi WS; Seo YB; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim MJ; Song JY
J Korean Med Sci; 2023 Oct; 38(42):e330. PubMed ID: 37904655
[TBL] [Abstract][Full Text] [Related]
38. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
Huijts SM; Coenjaerts FEJ; Bolkenbaas M; van Werkhoven CH; Grobbee DE; Bonten MJM;
Clin Microbiol Infect; 2018 Jul; 24(7):764-770. PubMed ID: 29050992
[TBL] [Abstract][Full Text] [Related]
39. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.
van Werkhoven CH; Bolkenbaas M; Huijts SM; Verheij TJM; Bonten MJM
Clin Microbiol Infect; 2021 Jul; 27(7):995-999. PubMed ID: 32971253
[TBL] [Abstract][Full Text] [Related]
40. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
